Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma

1

Diffuse large B-cell lymphoma (DLBCL) is the most prevalent lymphoma subtype in adults, with 30-40% of patients experiencing treatment resistance.
2

First-line treatments like R-CHOP and pola-R-CHP show low cross-resistance, indicating distinct resistance mechanisms among their components.
3

Polatuzumab vedotin resistance is primarily due to low CD79b expression and high levels of multidrug resistance pumps and anti-apoptotic proteins.
4

Rituximab resistance is linked to alterations in the MS4A1 gene and the CD20 antibody-binding site, affecting its mechanisms of action.
5

Understanding the molecular mechanisms of resistance is crucial for developing effective therapeutic strategies for DLBCL patients.